BioCardia, Inc.
BCDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $107 | $1,368 | $1,530 | $1,415 |
| Gross Profit | -$107 | -$1,368 | -$1,530 | -$1,415 |
| % Margin | – | – | – | – |
| R&D Expenses | $932 | $1,368 | $1,530 | $1,415 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $449 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$685 | -$334 | -$509 |
| Operating Expenses | $1,381 | $683 | $1,196 | $906 |
| Operating Income | -$1,488 | -$2,051 | -$2,726 | -$2,321 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | $2 | $14 | $25 |
| Pre-Tax Income | -$1,483 | -$2,049 | -$2,712 | -$2,296 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,483 | -$2,049 | -$2,712 | -$2,296 |
| % Margin | – | – | – | – |
| EPS | -236.23 | -0.4 | -0.99 | -0.84 |
| % Growth | -58,957.5% | 59.6% | -17.9% | – |
| EPS Diluted | -236.23 | -0.4 | -0.99 | -0.5 |
| Weighted Avg Shares Out | 6 | 5,060 | 2,744 | 2,744 |
| Weighted Avg Shares Out Dil | 6 | 5,060 | 2,744 | 2,744 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $107 | $5 | $12 | $15 |
| EBITDA | -$1,376 | -$2,046 | -$2,714 | -$2,306 |
| % Margin | – | – | – | – |